Cargando…

P1174: THE COMBINATION OF QUALITATIVE AND QUANTITATIVE METABOLIC PARAMETERS PREDICTS PROGRESSION-FREE SURVIVAL IN PATIENTS WITH LARGE B-CELL LYMPHOMAS (LBCL) TREATED WITH ANTI-CD19 CAR-T CELLS.

Detalles Bibliográficos
Autores principales:	Dodero, A., Guidetti, A., Lorenzoni, A., Pizzamiglio, S., Argiroffi, G., Verderio, P., Chiappella, A., Bagnoli, F., Carniti, C., Pennisi, M., Alessi, A., Corradini, P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430247/ http://dx.doi.org/10.1097/01.HS9.0000847560.15177.a7

Ejemplares similares

Combination of Deauville score and quantitative positron emission tomography parameters as a predictive tool of anti‐CD19 chimeric antigen receptor T‐cell efficacy
por: Guidetti, Anna, et al.
Publicado: (2022)

Phenotypic Composition of Commercial Anti-CD19 CAR T Cells Affects In Vivo Expansion and Disease Response in Patients with Large B-cell Lymphoma
por: Monfrini, Chiara, et al.
Publicado: (2022)

P1188: PERSONALIZED TREATMENT ACCORDING TO BIOLOGICAL PROFILE IMPROVES OUTCOME OF NEWLY DIAGNOSED PATIENTS AFFECTED BY DIFFUSE LARGE B-CELL LYMPHOMA: A REAL-LIFE EXPERIENCE
por: Guidetti, A., et al.
Publicado: (2022)

P1081: A MULTICENTER OBSERVATIONAL STUDY ON CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR LARGE B-CELL (LBCL) AND MANTLE CELL (MCL) LYMPHOMAS: THE ITALIAN CART-SIE REAL LIFE EXPERIENCE
por: Chiappella, Annalisa, et al.
Publicado: (2023)

P1744: ACCURACY OF PREDICTING LONG-TERM SURVIVAL OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPIES IN LARGE B-CELL LYMPHOMA (LBCL)
por: Verburg-Baltussen, E. J., et al.
Publicado: (2022)

Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Large B-Cell Lymphoma (LBCL): A Single-Institution Experience
por: Trando, Aaron, et al.
Publicado: (2023)

S228: POSITRON EMISSION TOMOGRAPHY EVALUATION IN A LARGE GROUP OF PATIENTS AFFECTED BY RELAPSED/REFRACTORY B-CELL LYMPHOMAS TREATED WITH ANTI-19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS THERAPY (CART SIE).
por: Dodero, Anna, et al.
Publicado: (2023)

P1448: LONG-TERM SURVIVORS AFTER FAILURE OF CAR-T CELL THERAPY FOR R/R LARGE B-CELL LYMPHOMA (LBCL): A GLA/DRST STUDY
por: Derigs, P., et al.
Publicado: (2022)

Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL
por: Perez, Ariel, et al.
Publicado: (2022)

High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression
por: Maura, F, et al.
Publicado: (2017)

Are We Ready to Treat Diffuse Large B-cell and High-Grade Lymphoma According to Major Genetic Subtypes?
por: Chiappella, Annalisa, et al.
Publicado: (2019)

Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma
por: Dodero, A., et al.
Publicado: (2019)

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
por: Rejeski, Kai, et al.
Publicado: (2022)

Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome
por: Dodero, Anna, et al.
Publicado: (2021)

P1458: PATTERNS OF LONG-TERM HEMATOPOIETIC RECOVERY IMPACT SURVIVAL OUTCOMES AFTER CD19-DIRECTED CAR T-CELL THERAPY FOR R/R LBCL
por: Rejeski, K., et al.
Publicado: (2022)

A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients
por: Pellegrini, Cinzia, et al.
Publicado: (2016)

P1125: DURABLES RESPONSES ACHIEVED WITH ANTI-CD19 ALLOGENEIC CAR T ALLO-501/501A IN PHASE 1 TRIALS OF AUTOLOGOUS CAR T-NAÏVE PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL)
por: Munoz, Javier, et al.
Publicado: (2023)

An Orthopedic Clinic of 1174 A.D.
por: Cravener, Edward K.
Publicado: (1931)

S231: PRIMARY MEDIASTINAL B-CELL LYMPHOMA HAVE A SUPERIOR OUTCOME COMPARED TO DIFFUSE LARGE-B-CELL LYMPHOMA TREATED WITH AXICABTAGENE CILOLEUCEL IN THE CART-SIE REAL LIFE ITALIAN STUDY
por: Chiappella, Annalisa, et al.
Publicado: (2023)

Efficacy and Safety of Innovative Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review
por: Weinstein, Bayarmagnai, et al.
Publicado: (2021)

ASCT vs CART for patients with relapsed LBCL in PR: role of TMTV
por: Strati, Paolo, et al.
Publicado: (2023)

P1197: AXICABTAGENE CILOLEUCEL (AXI-CEL) IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): OUTCOMES OF THE PHASE 2 ZUMA-14 STUDY
por: Strati, P., et al.
Publicado: (2022)

Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy
por: Marangon, Miriam, et al.
Publicado: (2021)

CDKN2A deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)
por: Maura, Francesco, et al.
Publicado: (2020)

CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma
por: Mohty, Razan, et al.
Publicado: (2022)

P1204: TREATMENT PATTERNS AND REAL-WORLD OUTCOMES IN PATIENTS (PT) WITH LARGE B-CELL LYMPHOMA (LBCL) WHO RECEIVED SECOND-LINE (2L) THERAPY
por: Lunning, M., et al.
Publicado: (2022)

Oncogenic ALK(F1174L) drives tumorigenesis in cutaneous squamous cell carcinoma
por: Gualandi, Marco, et al.
Publicado: (2020)

Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL
por: Abramson, Jeremy S., et al.
Publicado: (2022)

Lenalidomide in Diffuse Large B-Cell Lymphomas
por: Chiappella, Annalisa, et al.
Publicado: (2012)

CAR T-cells: Driving in the Fast Lane
por: Ansell, Stephen M., et al.
Publicado: (2019)

Liu Sung-nien (1174–1224), Sung Dynasty. Lohan (1207)
por: Potter, Polyxeni
Publicado: (2004)

SG-APSIC1174: High-value instrument management: Rigid endoscopes
por: Sirijindadirat, Nanthipha
Publicado: (2023)

Intensified therapy in diffuse large B-cell lymphoma
por: Novo, Mattia, et al.
Publicado: (2017)

CAR T-Cell therapy for the management of mantle cell lymphoma
por: Huang, Zoufang, et al.
Publicado: (2023)

P1710: LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE TREATMENT FOR R/R LARGE B-CELL LYMPHOMA (LBCL) IN PATIENTS NOT INTENDED FOR HSCT: PATIENT-REPORTED OUTCOMES (PRO) FROM THE PHASE 2 PILOT STUDY
por: Gordon, L. I., et al.
Publicado: (2022)

Data Rates Between the ISR Equipment and the Control System (Runs 1174 and 1175)
por: Kemp, D
Publicado: (1981)

Molecular Modeling for Structural Insights Concerning the Activation Mechanisms of F1174L and R1275Q Mutations on Anaplastic Lymphoma Kinase
por: Jiang, Cheng-Han, et al.
Publicado: (2018)

Deciphering the Mechanism of Gilteritinib Overcoming Lorlatinib Resistance to the Double Mutant I1171N/F1174I in Anaplastic Lymphoma Kinase
por: Liang, Shuai, et al.
Publicado: (2021)

P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY
por: Hutchings, Martin, et al.
Publicado: (2023)

T‐cell immune response after mRNA SARS‐CoV‐2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies
por: Marasco, Vincenzo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9h4ibpgirdoc2v4m7apn8kp7q7